.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
ScreenPoint Medical highlights Transpara regulatory clearances
Transpara Detection can be used as decision support, as an independent second reader, to optimize workflow, and more.
.png)
AI increases breast cancer detection – with Dr. Cathy Keller
Dr. Cathy Keller discusses how breast AI is used to improve breast screening accuracy and offers key recommendations for awareness and action.
.png)
AI can act as your second reader for breast cancer screening programmes
As leading breast cancer screening programmes look to adapt and advance, Breast AI may serve as a lifeline to better workflow and improved health outcomes.
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
Transpara Breast AI is the technology of choice for first large-scale RCT in the United States to evaluate the role of AI in breast cancer screening.
.png)
ScreenPoint Medical expands in Spain with SACYL - EUSOBI 2025
ScreenPoint Medical partners with SACYL to bring AI for breast cancer detection to Castilla y León, enhancing screening accuracy and efficiency in Spain.
.png)
New study assesses cost-effectiveness of Transpara as part of national screening protocol
Is it possible to reduce the total cost for the healthcare system and simultaneously boost quality-adjusted life years across a population?